These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 25209423)

  • 1. Optimal design of clinical trials with biologics using dose-time-response models.
    Lange MR; Schmidli H
    Stat Med; 2014 Dec; 33(30):5249-64. PubMed ID: 25209423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of clinical trials with biologics using dose-time-response models.
    Lange MR; Schmidli H
    Stat Med; 2015 Sep; 34(22):3017-28. PubMed ID: 26059422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bayesian optimal designs for a quantal dose-response study with potentially missing observations.
    Baek I; Zhu W; Wu X; Wong WK
    J Biopharm Stat; 2006; 16(5):679-93. PubMed ID: 17037265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design considerations and analysis planning of a phase 2a proof of concept study in rheumatoid arthritis in the presence of possible non-monotonicity.
    Liu F; Walters SJ; Julious SA
    BMC Med Res Methodol; 2017 Oct; 17(1):149. PubMed ID: 28969588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statistical designs for early phases of cancer clinical trials.
    Guan S
    J Biopharm Stat; 2012; 22(6):1109-26. PubMed ID: 23075011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple-objective designs in a dose-response experiment.
    Zhu W; Wong WK
    J Biopharm Stat; 2000 Feb; 10(1):1-14. PubMed ID: 10709797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal designs for estimating the interesting part of a dose-effect curve.
    Miller F; Guilbaud O; Dette H
    J Biopharm Stat; 2007; 17(6):1097-115. PubMed ID: 18027219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of dose-response for count data using a generalized MCP-Mod approach in an adaptive dose-ranging trial.
    Mercier F; Bornkamp B; Ohlssen D; Wallstroem E
    Pharm Stat; 2015; 14(4):359-67. PubMed ID: 26083135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypothesis testing and Bayesian estimation using a sigmoid Emax model applied to sparse dose-response designs.
    Thomas N
    J Biopharm Stat; 2006; 16(5):657-77. PubMed ID: 17037264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Bayesian adaptive dose selection procedure with an overdispersed count endpoint.
    Pozzi L; Schmidli H; Gasparini M; Racine-Poon A
    Stat Med; 2013 Dec; 32(28):5008-27. PubMed ID: 24022748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adaptive dose selection using efficacy-toxicity trade-offs: illustrations and practical considerations.
    Thall PF; Cook JD; Estey EH
    J Biopharm Stat; 2006; 16(5):623-38. PubMed ID: 17037262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal adaptive design in clinical drug development: a simulation example.
    Maloney A; Karlsson MO; Simonsson US
    J Clin Pharmacol; 2007 Oct; 47(10):1231-43. PubMed ID: 17906158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Bayesian design and analysis for dose-response using informative prior information.
    Smith MK; Marshall S
    J Biopharm Stat; 2006; 16(5):695-709. PubMed ID: 17037266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Bayesian adaptive design for multi-dose, randomized, placebo-controlled phase I/II trials.
    Xie F; Ji Y; Tremmel L
    Contemp Clin Trials; 2012 Jul; 33(4):739-48. PubMed ID: 22426247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bayesian adaptive D-optimal design with delayed responses.
    Li J; Fu H
    J Biopharm Stat; 2013 May; 23(3):559-68. PubMed ID: 23611195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An adaptive dose-finding design incorporating both toxicity and efficacy.
    Zhang W; Sargent DJ; Mandrekar S
    Stat Med; 2006 Jul; 25(14):2365-83. PubMed ID: 16220478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PFIM 4.0, an extended R program for design evaluation and optimization in nonlinear mixed-effect models.
    Dumont C; Lestini G; Le Nagard H; Mentré F; Comets E; Nguyen TT;
    Comput Methods Programs Biomed; 2018 Mar; 156():217-229. PubMed ID: 29428073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An extension of Bayesian predictive sample size selection designs for monitoring efficacy and safety.
    Teramukai S; Daimon T; Zohar S
    Stat Med; 2015 Sep; 34(22):3029-39. PubMed ID: 26038148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomarker-based Bayesian randomized phase II clinical trial design to identify a sensitive patient subpopulation.
    Morita S; Yamamoto H; Sugitani Y
    Stat Med; 2014 Oct; 33(23):4008-16. PubMed ID: 24820639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A case study of model-based Bayesian dose response estimation.
    Tan H; Gruben D; French J; Thomas N
    Stat Med; 2011 Sep; 30(21):2622-33. PubMed ID: 21713966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.